{"id":"NCT00579345","sponsor":"Novartis","briefTitle":"Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup","officialTitle":"A Phase III, Single-Blind, Multi-Center, Extension Study to Evaluate Safety and Tolerability of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adult and Elderly Subjects Who Participated in Study V58P4, With Subset Analyses of Immunogenicity and Evaluation of Concomitant Polysaccharide Pneumococcal Vaccine (Elderly).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2007-12-24","resultsPosted":"2011-10-10","lastUpdate":"2017-01-27"},"enrollment":1522,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Cell culture derived seasonal trivalent influenza vaccine (cTIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).","otherNames":[]},{"type":"BIOLOGICAL","name":"cTIV or eTIV_a","otherNames":[]},{"type":"BIOLOGICAL","name":"cTIV+PV OR eTIV_a+PV","otherNames":[]}],"arms":[{"label":"cTIV","type":"EXPERIMENTAL"},{"label":"eTIV_a","type":"ACTIVE_COMPARATOR"},{"label":"FLU (cTIV or eTIV_a)","type":"EXPERIMENTAL"},{"label":"FLU (cTIV or eTIV_a) + PV","type":"ACTIVE_COMPARATOR"}],"summary":"The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV\\_a)) when administered alone and when administered concomitantly with pneumococcal polysaccharide vaccine (PV) in elderly subjects. The study also aimed to evaluate safety and immunogenicity (subset) of annual vaccination with either cTIV or eTIV\\_a in adults and elderly subjects.","primaryOutcome":{"measure":"Number of Randomized Participants Reporting Local and Systemic Reactions.","timeFrame":"One week postvaccination","effectByArm":[{"arm":"cTIV Total (Elderly)","deltaMin":52,"sd":null},{"arm":"eTIV_a Total (Elderly)","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":5,"countries":["Poland"]},"refs":{"pmids":["22418809"],"seeAlso":["http://www.ncbi.nlm.nih.gov/pubmed/?term=22418809"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":550},"commonTop":["Injection site pain","Injection site erythema","Malaise","Headache","Injection site induration"]}}